Bio-Rad Laboratories, Inc. Press Releases

BIO 
$119.86
*  
0.08
 negative 
0.07%
Get BIO Alerts
*Delayed - data as of Apr. 16, 2014 
Exchange: NYSE
Industry: Capital Goods
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Bio-Rad to Report First-Quarter 2014 Financial Results Tuesday, May 6, 2014
4/16/2014 12:32:00 PM - Market Wire

BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company
4/16/2014 1:00:00 AM - Business Wire

BioAlliance Pharma Announces a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer
4/14/2014 12:11:00 PM - Business Wire

Bio-Rad Acquires GnuBIO, Developer of Droplet-Based DNA Sequencing Technology
4/11/2014 8:41:00 AM - Business Wire

Bio-Rad Acquires GnuBIO and DNA Sequencing Technology
4/10/2014 8:00:00 PM - Market Wire

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea
4/2/2014 2:00:00 AM - Business Wire

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®
4/1/2014 1:00:00 PM - Business Wire

BioAlliance Pharma Collaborates with Penn Pharma on the Industrial Development of Validive®
3/31/2014 12:06:00 PM - Business Wire

BioAlliance Pharma announces participation in the Smallcap Event On April 7th and 8th 2014 in Paris
3/28/2014 1:00:00 PM - GlobeNewswire

BioAlliance Pharma: Sitavig® Licensing Strategy
3/19/2014 2:00:00 AM - Business Wire

Bio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results
2/27/2014 4:15:00 PM - Market Wire

BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results
2/27/2014 12:00:00 PM - Business Wire

BioAlliance Pharma SA: Strengthening and extension of the industrial protection of Livatag® until 2031
2/18/2014 12:00:00 PM - Business Wire

BioAlliance Pharma’s Partner, Sosei, Announces a Partnership With FUJIFILM Pharma for Commercialization Rights for Loramyc® in Japan
2/4/2014 12:00:00 PM - Business Wire

Bio-Rad to Report Fourth-Quarter and Full-Year 2013 Financial Results Thursday, February 27, 2014
1/27/2014 7:43:00 PM - Market Wire

BioAlliance Pharma : FDA Grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments
1/23/2014 1:00:00 AM - Business Wire